Big Pharma and Pandemic Preparedness: Addressing the Lack of Incentive
Monday, 9 September 2024, 21:11
Big Pharma’s Role in Pandemic Readiness
Despite recent global health crises, Big Pharma
lacks motive to effectively prepare for new pandemics. The devastating toll of the Covid-19 pandemic, which resulted in approximately 16 million deaths, underscored the critical importance of vaccines.
The Continuing Threat of Disease Outbreaks
The ongoing fears surrounding Mpox emphasize how the public remains anxious about potential new outbreaks. Vaccination plays a vital role in combating these threats, yet there is a concerning trend of unpreparedness within the pharmaceutical industry.
Factors Contributing to Complacency
- Economic Incentives: There is little financial motivation for pharmaceutical companies to invest in pandemic preparedness.
- Public Health Policy: Insufficient government regulations fail to encourage proactive measures.
- Market Trends: A focus on chronic disease treatments often overshadows the need for vaccines.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.